Recombinant Human IL-8/CXCL8 Protein (E.coli) (PKSH030277)
For research use only.
| Synonyms | CXCL, Interleukin, C-X-C motif chemokine, Chemokine (C-X-C motif) ligand, IL8/CXCL, GCP, NAP, CXCL8, GCP-1, GCP1, IL8, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, 3-10C, AMCF-I, IL8/CXCL8, K60, Interleukin-8, IL-8, Emoctakin, C-X-C motif chemokine 8, Chemokine (C-X-C motif) ligand 8, Granulocyte chemotactic protein 1 (GCP-1), Monocyte-derived neutrophil chemotactic factor (MDNCF), (Ala-IL-8)77, (Ser-IL-8)72, 9E3, Beta thromboglobulin like protein, CEF-4, chemokine, CXC motif, GCP/IL-8 protein I, GCP/IL-8 protein II, GCP/IL-8 protein III, GCP/IL-8 protein IV, GCP/IL-8 protein V, GCP/IL-8 protein VI, Granulocyte chemotactic protein 1, IL-8(1-77), IL-8(9-77), IL8/NAP1 form I, IL8/NAP1 form II, IL8/NAP1 form III, IL8/NAP1 form IV, IL8/NAP1 form V, IL8/NAP1 form VI, Inteleukin 8, ligand 8, Lymphocyte-derived neutrophil-activating factor, MDNCF-b, MDNCF-c, Monocyte-derived neutrophil chemotactic factor, Monocyte-derived neutrophil-activating peptide, Neutrophil activating peptide 1, Neutrophil activating protein 1, Neutrophil-activating factor, Neutrophil-activating protein 1, Protein 3 10C, Protein 3-10C, SCYB8, Small inducible cytokine subfamily B member 8, T cell chemotactic factor, T-cell chemotactic factor, TSG1 |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Ser 28-Ser 99 |
| Accession | NP_000575.1 |
| Calculated Molecular Weight | 8.5 kDa |
| Tag | None |
| Bio-activity | Not validated for activity |
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation |
Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
| Background | Interleukin 8 (IL-8), also known as CXCL8, which is a chemokine with a defining CXC amino acid motif that was initially characterized for its leukocyte chemotactic activity, is now known to possess tumorigenic and proangiogenic properties as well. This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli. In human gliomas, IL-8 is expressed and secreted at high levels both in vitro and in vivo, and recent experiments suggest it is critical to glial tumor neovascularity and progression. Levels of IL-8 correlate with histologic grade in glial neoplasms, and the most malignant form, glioblastoma, shows the highest expression in pseudopalisading cells around necrosis, suggesting that hypoxia/anoxia may stimulate expression. Accumulating evidence has demonstrated that various types of cells can produce a large amount of IL-8/CXCL8 in response to a wide variety of stimuli, including proinflammatory cytokines, microbes and their products, and environmental chang. Numerous observations have established IL-8/CXCL8 as a key mediator in neutrophil-mediated acute inflammation due to its potent actions on neutrophils. The discovery of these biological functions suggests that IL-8/CXCL8 has crucial roles in various pathological conditions such as chronic inflammation and cancer. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
